174 results about "Phosphatidyl Cholines" patented technology

The invention discloses a phosphatidylcholine gold nano CT (Computed Tomography) probe as well as a preparation method and application thereof, and belongs to the technical field of medical materials. The preparation method comprises the following steps: step S1, preparing a phosphatidylcholine ligand NH2-MPC; step S2, synthesis of a gold nanocluster GS-Au25 is carried out; and S3, the GS-Au25 is modified with a PC ligand, and the PC-Au25 is prepared. The ultra-small gold nano CT probe PC-Au25 with an Au25 gold nano cluster as a core and phosphatidylcholine PC as a surface ligand is obtained by optimizing and screening the core size and the surface ligand property of ultra-small gold nano particles. Wherein the 2-methacryloyloxyethyl phosphorylcholine is used as a PC ligand for the first time to modify the surfaces of the ultra-small gold nanoparticles, so that the surface modification of the ultra-small gold nanoparticles is realized, and the ultra-small gold nanoparticles can be efficiently and freely filtered through the kidney. The CT probe can be applied to the determination of the glomerular filtration rate through a CT imaging or blood test method.

The invention provides electroactive nano short fibers for osteoarthritis cartilage repair and a preparation method thereof, the preparation method comprises the following steps: preparing a nano fiber membrane from a composite material of gelatin, polylactic acid and glycine crystals through electrostatic spinning, and preparing the obtained nano fiber membrane into short fibers; performing freeze drying on the short fibers, and then performing heating treatment to obtain a short fiber stent; the short fiber support is smashed and reacts with graphene oxide, modified graphene oxide short fibers are obtained, and then the modified graphene oxide short fibers are soaked in a mixed solution of alkaline dopamine and phosphatidylcholine for a reaction. The electroactive nano short fiber provided by the invention is low in friction coefficient, the expression quantity of Sirt1 in OA cartilage cells can be remarkably increased under ultrasonic stimulation, the ATP (adenosine triphosphate) productivity can be remarkably improved, release of inflammatory factors and degradation of extracellular matrixes can be inhibited, and meanwhile, a guarantee is provided for updating of a hydrated lubricating layer.

The invention relates to the technical field of biological pharmacy, and discloses a QS-21 saponin adjuvant as well as a preparation method and application thereof, the adjuvant is a composite liposome and comprises a liposome skeleton composed of distearoyl phosphatidylcholine and cholesterol, and QS-21 saponin, monophosphoryl lipid A and a local anesthetic are jointly entrapped in the liposome skeleton. The problem that high reactogenicity and immunogenicity of potent adjuvants are difficult to consider at the same time is solved, the immunostimulation component and the pain inhibition component are jointly entrapped in the same nano-carrier, collaborative delivery in injection local is achieved, and therefore pain and swelling caused by the adjuvants are accurately inhibited. The co-entrapment structure avoids the potential inhibition effect of the free anesthetic on the immune system, the potent body fluid and cellular immune enhancement activity of the adjuvant is completely reserved, and a new technical scheme is provided for developing vaccines with high safety and strong immune efficacy.

The invention discloses a special ultralow-temperature preservative for blood T cells and application of the special ultralow-temperature preservative, and the special ultralow-temperature preservative comprises the following components in percentage by mass and volume: an osmotic pressure regulating system (5-10% of glycerol and 10-20% of glycolalcohol which are compounded); an antioxidant protection system (10%-20% of human serum albumin and 0.1%-1% of glutathione); a nutrition supply agent (a cell culture medium containing glucose, amino acid, vitamin and electrolyte); a pH stable buffer pair (0.5%-3% of HEPES and 0.1%-1% of sodium bicarbonate); and a cell membrane enhancer (1%-1% of cholesterol and 0.05%-0.5% of phosphatidylcholine). The pH value of the preservative is 7.2-7.4, the preservative is suitable for long-time cryopreservation of blood T cells at the ultralow temperature of-80 DEG C to-196 DEG C, and the biological activity and functional integrity of the T cells can be effectively maintained. The invention also relates to an application of the preservative in preparation of T cell preparations preserved at ultra-low temperature, and the survival rate and functional integrity of cells after cryopreservation can be obviously improved.

The invention discloses a lipid composition for preparing extracellular vesicles, which is prepared from the following lipid substances in percentage by mass: 2 to 18 percent of phosphatidylcholine, 2 to 14 percent of phosphatidylethanolamine, 7 to 27 percent of sphingomyelin, 0.5 to 7 percent of ceramide, 1.5 to 2.5 percent of phosphatidylinositol, 30 to 70 percent of cholesterol and 5 to 8 percent of phosphatidylserine, the fatty acid carbon number of the lipid substance satisfies the following conditions: the fatty acid carbon number of phosphatidylcholine is 16-20, the fatty acid carbon number of phosphatidyl ethanolamine is 16-18, the fatty acid carbon number of sphingomyelin is 16-24, the fatty acid carbon number of ceramide is 16-24, the fatty acid carbon number of phosphatidylinositol is 16-20, the fatty acid carbon number of phosphatidylserine is 18-24, and the molar ratio of cholesterol to sphingomyelin is 4-7. The extracellular vesicles are prepared from the lipid composition and used for biomarkers or drug carriers, and efficient oral drug delivery is achieved.

The invention discloses a composition containing a polypeptide exosome and application of the composition in preparation of a product with skin repair ability, and particularly relates to the technical field of biology, the composition comprises polypeptide-exosome composite nanoparticles, and a polypeptide containing a GRGDS motif and an umbilical cord Wharton's jelly exosome are covalently crosslinked; the lipid double-layer coating layer comprises phosphatidylcholine, cholesterol and PEG-2000, and the molar ratio of the phosphatidylcholine to the cholesterol to the PEG-2000 is 5: 3: 2; the synergist is prepared from 0.1 to 5 percent of epicatechin gallate and 2 to 8 percent of recombinant collagen III oligopeptide. The nano-liposome is prepared through microfluidic self-assembly and a film hydration-ultrasonic intercalation method, and can be loaded on a degradable microneedle patch, so that targeted slow release of a wound part is realized. Through the synergistic effect of targeted delivery, oxidation resistance and collagen regeneration, the skin repair efficiency is remarkably improved, and the healing time is shortened.

Provided herein are lipid nanoparticle (LNP) compositions (e.g., pharmaceutical compositions) comprising a therapeutic nucleic acid (TNA), wherein the LNP comprises an ionizable lipid; a "helper" lipid, e.g., a ceramide or distearoylphosphatidylcholine (DSPC); a structural lipid, e.g., a sterol; and one or more types of lipid-anchored polymers, as well as uses thereof.

The invention discloses an emulsifier for preparing a Pickering emulsion, the Pickering emulsion as well as a preparation method and application of the Pickering emulsion. The emulsifier of the Pickering emulsion is obtained by dissolving distearoyl phosphatidylcholine, cholesterol and distearoyl phosphatidyl ethanolamine-polyethylene glycol 2000 in ethanol, carrying out rotary evaporation to remove ethanol, then adding an antigen aqueous solution containing an antigen, continuing rotary evaporation to obtain liposome nanoparticles, heating the liposome nanoparticles with mannose in a water bath, and carrying out freeze drying. The Pickering emulsion is obtained by dispersing an emulsifier in water as a water phase, taking squalene as an oil phase, mixing the water phase and the oil phase, and homogenizing. The Pickering emulsion disclosed by the invention is prepared by taking antigen presenting cell targeted liposome nanoparticles as a raw material; and the antigen has excellent ion concentration characteristic, pH stability, temperature stability and storage stability, and can protect the integrity of the antigen.

The invention relates to the field of synthetic phospholipids, in particular to a synthetic phosphatidylcholine-like refining method which comprises the following steps: A, dissolving: adding a mixed solvent into synthetic phosphatidylcholine-like, and stirring for dissolving to obtain a crude product solution; b, complexing: adding a metal salt into the crude product solution, mixing, and continuously stirring for dissolving to obtain a primary refined solution; c, crystallization: adding an indissolvable organic solvent into the primary refined liquid, then cooling for crystallization, and carrying out solid-liquid separation to obtain solid crystals; and D, cleaning: rinsing and drying the solid crystal to obtain a refined phosphatidylcholine product. The refining method provided by the invention is green in process and low in cost, and high-purity synthetic phosphatidylcholine with the purity of 98% or above is obtained.

The present invention relates to a lipid nanoparticle composition comprising sodium DNA, and more particularly, to a lipid nanoparticle composition comprising: sodium DNA as an active ingredient; the sodium bis (lauramide glutamine) lysine is used as an amphiphilic surfactant; the distearoyl phosphatidylcholine is used as an auxiliary surfactant; cholesterol as a stabilizer; the auxiliary stabilizer is selected from the group consisting of PEG-120 stearate, polyglycerol-4 decanoate, a poly (ethylene glycol)-poly (epsilon-caprolactone) copolymer (PEG-PCL copolymer) and a mixture of the PEG-120 stearate, the polyglycerol-4 decanoate and the poly (ethylene glycol)-poly (epsilon-caprolactone) copolymer; and a solvent.

The invention discloses a lipid composition, lipid nanoparticles, a preparation method of the lipid nanoparticles, a pharmaceutical composition, a pharmaceutical preparation and application. The lipid composition is prepared from a cationic lipid SM-102, a cationic lipid NT-O14B, cholesterol, distearoyl phosphatidylcholine (DSPC) and a phospholipid polyethylene glycol (PEG) derivative. The invention provides the lipid composition which can be applied to preparation of lipid nanoparticles for brain delivery, through optimal combination of specific lipid components, the efficiency of penetrating through the blood brain barrier during LNP drug delivery is improved, reliable technical support is provided for application of siRNA drugs in nervous system diseases, and the lipid composition has the application prospect of promoting treatment of the nervous system diseases.

The invention belongs to the technical field of cosmetics, particularly discloses moisturizing nano-liposome emulsion prepared by a microjet method and a preparation method of the moisturizing nano-liposome emulsion, and aims to solve the problems of poor stability of active ingredients, low transdermal absorption efficiency, single effect and non-uniform particle size in a liposome preparation process in the existing moisturizing cosmetics. The nano-liposome emulsion is prepared from glycosylglycerol, acetylchitosamine, tremella polysaccharide, a myrothamnus flabellifolia leaf / stem extract, an artemisia annua extract, a lactobacillus fermentation product, flat nuclear wood oil, hydrogenated lecithin and phosphatidylcholine. The emulsion has excellent moisturizing, soothing and repairing effects, can be used for preparing skin care products such as water aqua, emulsion and cream, and has the advantages of high utilization rate of active ingredients and good stability.

The invention discloses a negative ion metabolism marker for thyroid-associated ophthalmopathy, a product and application of the negative ion metabolism marker. The metabolic marker is prepared from any one or more of 7alpha, 17alpha-dimethyl-5beta-androstane-3 alpha, 17beta-diol, N, N-dimethyl phosphatidyl ethanolamine, 15 (S)-hydroxy eicosatrienoic acid and 1-myristoyl-2-[(9Z)-octadecenoyl]-sn-glycerol-3-phosphatidylcholine, and the metabolic marker is prepared from any one or more of the following raw materials: 1-myristoyl-2-[(9Z)-octadecenoyl]-sn-glycerol-3-phosphatidylcholine. The invention provides a kit which comprises a detection reagent for detecting the negative ion metabolism marker. The invention provides a computer program product for thyroid-related eye diseases. The product provided by the invention has good feasibility and accuracy, can effectively evaluate the risk of thyroid-related eye diseases, and provides a new tool for clinical diagnosis.

The present invention provides a kind of composition containing bird's nest acid, phospholipid and polyunsaturated fatty acid and preparation method thereof, composition, when not adding any additives, bird's nest acid is dispersed in DHA grease in functional ingredients, while solving the problem that DHA is easily oxidized, promotes brain development, regulates immunity, promotes the absorption and utilization of minerals in the intestine and the effects of beauty and skin care. Phospholipids can prevent the sedimentation of bird's nest acid in ω 3 polyunsaturated fatty acid grease, and are phosphatidylcholine, phosphatidylethanolamine, phosphatidylinositol or phosphatidylserine. Not only can the sedimentation of bird's nest acid be prevented, but also the growth of nerve cells can be supported, thereby improving the absorption rate of DHA in the brain. Especially PS, itself can not only nourish the brain, enhance brain function, but also relieve mental stress and improve cognition, and is called "brain nutrient".

This invention relates to the field of biopharmaceutical technology, disclosing a QS-21 saponin adjuvant, its preparation method, and its applications. The adjuvant is a composite liposome comprising a liposome backbone composed of distearate phosphatidylcholine and cholesterol, with QS-21 saponin, monophosphatidyllipid A, and a local anesthetic co-encapsulated therein. This invention solves the common problem of high reactivity and immunogenicity in potent adjuvants by co-encapsulating immunostimulatory and analgesic components on the same nanocarrier, achieving synergistic delivery at the injection site, thereby precisely inhibiting adjuvant-induced pain and swelling. This co-encapsulation structure avoids the potential inhibitory effect of free anesthetics on the immune system, fully preserving the adjuvant's potent humoral and cellular immune-enhancing activity. This invention provides a new technical solution for developing vaccines with both high safety and strong immunogenicity.

The application discloses a kind of artificial cells for single-cell mass spectrometry and preparation method thereof, wherein artificial cell includes internal water phase, intermediate oil phase and external water phase;Internal water phase includes polyethylene glycol and polyvinyl alcohol aqueous solution, intermediate oil phase includes L-alpha-phosphatidylcholine chloroform and hexane mixture;External water phase includes PVA and F-68 aqueous solution.Compared with natural cell sample, the novel artificial single cell based on microfluidic self-assembly developed in the application has better uniformity, stability and controllability, effectively avoids significant measurement difference between single-cell individual samples, and effectively solves the problem of difficult stable preservation of biological samples.The proposed artificial cell preparation method will largely solve the problem of lack of standard reference material in the field of single-cell mass spectrometry, making the results of single-cell mass spectrometry method more accurate, reliable and mutually recognized.

The invention discloses an acute kidney injury nuclear magnetic resonance detection contrast agent as well as a preparation method and application thereof. The lipidosome comprises a first lipid component and a second lipid component, the first lipid component is any one of 1, 2-dipalmitoyl-sn-glycerol-3-phosphorylcholine, 1, 2-dioleoyl-sn-glycerol-3-phosphorylcholine and distearoyl phosphatidylcholine, and the second lipid component is a sterol derivative, and the first lipid component is any one of 1, 2-dipalmitoyl-sn-glycerol-3-phosphorylcholine, 1, 2-dioleoyl-sn-glycerol-3-phosphorylcholine and distearoyl phosphatidylcholine. The molar ratio of the first lipid component to the second lipid component is (1-3): 1. According to the invention, all organic free radicals are used for replacing gadolinium ions, so that renal toxicity and systemic fibrosis risks caused by metal accumulation are eliminated, and the method is especially suitable for imaging of patients with renal insufficiency. The material synthesis process is simple, and the cost is controllable. In addition, the system is seamlessly compatible with clinical 3.0 T MRI equipment, additional hardware transformation is not needed, and popularization and application of AKI bedside rapid imaging diagnosis can be directly promoted.

The invention provides a nutritional composition capable of influencing protein expression of brain hippocampus and application of the nutritional composition. The nutritional composition of the present invention comprises sialic acid, sphingomyelin and phosphatidylcholine, in which the ratio of the sum of the contents of sphingomyelin and phosphatidylcholine to the content of sialic acid is 1: 1 by weight, and the ratio of sphingomyelin to phosphatidylcholine is 0.2: 1 to 1.4: 1 based on the total weight of sphingomyelin and phosphatidylcholine. The composition can increase the gray matter volume of the brain and can improve the expression of BDNFmRNA of the hippocampus and the prefrontal cortex.

The invention provides an application of phosphatidylcholine 36: 1 in prevention and treatment of senescence cognitive impairment, and particularly relates to an application of phosphatidylcholine 36: 1 or a pharmaceutical composition containing phosphatidylcholine 36: 1 in preparation of drugs for prevention and / or treatment of senescence cognitive impairment. The phosphatidylcholine 36: 1 can improve the level of superoxide dismutase and glutathione peroxidase in the brain of the mouse and reduce the lipid oxidation level at the same time. After the phosphatidylcholine 36: 1 is used for treatment, the levels of inflammatory factors interleukin 1 beta, interleukin 6 and tumor necrosis factor alpha in the brain are obviously reduced. Meanwhile, neurotransmitter disorder in brains of senescent mice can be remarkably improved. After qRT-PCR analysis is carried out in the brain of a mouse, it is found that after phosphatidylcholine 36: 1 treatment, the senescence gene level is remarkably reduced, the pro-apoptosis gene level is remarkably reduced, and the anti-apoptosis gene level is remarkably increased. And after in vitro administration of phosphatidylcholine 36: 1 to mouse hippocampal neuronal cells, no cytotoxicity is found. Therefore, the phosphatidylcholine 36: 1 can be used for preventing and treating senescence cognitive impairment.

The application discloses a kind of recombinant collagen glycerol body and preparation method thereof.The recombinant collagen glycerol body is 100 parts by total weight, and is composed of 2.7-3.7 parts of recombinant collagen, 5-15 parts of glycerol, 3.0-4.0 parts of L-alpha-phosphatidylcholine, 0.55-0.75 parts of emulsion regulator cetyl alcohol, 2 parts of preservative 1,2-pentanediol and 0.5 parts of 1,2-hexanediol, 0.05-0.10 parts of thickening agent xanthan gum, 0.1 parts of sodium chloride and 75.05~84.9 parts of purified water, and is prepared by water phase precipitation method.The application uses glycerol body as the carrier of recombinant collagen, which can improve the stability of recombinant collagen on one hand, and promote the transdermal absorption of recombinant collagen on the other hand.

This invention discloses a method for preparing a composite spray that improves hemostasis at wound sites. The composite spray includes solution A and solution B, where solution B is an aqueous solution of sodium alginate. The preparation method of solution A includes: 1. Dissolving a lipopeptide conjugate, cholesterol, distearylphosphatidylcholine, distearylphosphatidylserine, and dimethyl sulfoxide in a chloroform-methanol mixed solution to obtain a mixed system; 2. Preparing a precursor solution from the mixed system using a thin-film hydration method; 3. Adding calcium chloride to the precursor solution and reacting it in the dark to obtain solution A. This invention designs the precursor solution based on the function of natural platelets, and its function is equivalent to that of nanoplatelets. Combined with sodium alginate, it can specifically alleviate the adverse effects on the coagulation system caused by blood loss, such as fibrin degradation and reduced platelet activation, at wound sites. It has the characteristics of rapid hemostasis, good bioactivity, and rapid wound healing.

The invention discloses a cholesterol modified double-stranded DNA membrane skeleton liposome delivery system and a preparation method and application thereof, and belongs to the technical field of drug delivery. The system is composed of cholesterol, distearoyl phosphatidylcholine, distearoyl phosphatidyl ethanolamine modified by methoxy polyethylene glycol and double-stranded DNA (chol-dsDNA) modified by 5 '-cholesterol, and the chol-dsDNA is anchored on the inner side and the outer side of a liposome membrane through a hydrophobic effect to form a bionic skeleton. The system is excellent in mechanical stability, low in drug leakage rate, high in tumor targeted enrichment capacity and good in biocompatibility, can efficiently entrap irinotecan hydrochloride and other hydrophilic drugs, is used for tumor treatment, and is simple and convenient to prepare and easy to scale.

The present invention relates to ophthalmic compositions comprising at least one substance of at least one nicotinic acetylcholine receptor (nAChR) modulator, in particular varenicline, megamine and derivatives thereof, and / or the endogenous Kennedy metabolic pathway, as well as salts and derivatives or pharmaceutically acceptable salts of these substances, and choline-containing phospholipids, salts and derivatives of these substances. From these groups, particularly preferred are choline, phosphocholine, CDP-choline (citicoline), phosphatidylcholine (e.g. Lecithin having a phosphatidylcholine content of > = 80% by weight, e.g. Soybean lecithin), ethanolamine, phosphoethanolamine, CDP-ethanolamine, phosphatidylethanolamine, L-alpha-glycerophosphorylcholine, phosphatidylcholine, phosphatidylethanolamine.

The present disclosure describes PLPC-DB, an ultrapure phospholipoproteomic composition consisting of essential phospholipids, bioactive proteins, and intercellular regulatory factors, derived from the supernatant of peripheral blood mononuclear cells (PBMCs). This composition achieves a purity level exceeding 99% through a patented purification process that integrates high-speed advanced centrifugation and selective ultrafiltration, ensuring the structural stability and functional integrity of its bioactive components. PLPC-DB is optimized for advanced research and diagnostic applications, providing reproducibility, consistency, and safety across multicenter studies. The essential biomolecular components of PLPC-DB include phosphatidylcholine and phosphatidylserine, which contribute to membrane stability and intracellular signaling, while cell communication peptides enhance intercellular signaling, homeostatic regulation, and biochemical coordination. Structural and regulatory lipids support cell membrane biogenesis and functional stability, whereas adhesion and signaling proteins mediate cell-cell interactions and immune response coordination. Additionally, bioactive regulatory factors modulate immune and inflammatory responses, contributing to tissue regeneration and metabolic homeostasis.

The invention discloses a preparation method of a DNA (deoxyribonucleic acid) vaccine for preventing canine distemper, which comprises the following steps: taking plasmids of genes containing a newly separated canine distemper virus strain, namely a canine distemper virus fusion protein with an amino acid sequence shown as SEQ ID NO.6 and / or a hemagglutinin protein with an amino acid sequence shown as SEQ ID NO.8 as immunogens; hUO, mPEG-DMG, distearoyl phosphatidylcholine and cholesterol are used as lipid materials to prepare the canine distemper lipid nanoparticle DNA vaccine, and the vaccine can effectively stimulate neutralizing antibodies of mice, dogs, foxes and raccoon dogs and has clinical practical prospects.

The invention provides a contact lens with a surface hydrophilic coating and a preparation method thereof, and relates to the technical field of contact lenses. The preparation method comprises the following steps: mixing an acrylate monomer, a fluorine-containing siloxane compound, an initiator I, a cross-linking agent, glycerol and water to obtain a pre-polymerized solution I; mixing an unsaturated ester compound, N-vinyl pyrrolidone, polyvinyl alcohol, phosphatidylcholine, an initiator II, alcohol and dimethyl sulfoxide to obtain a pre-polymerized solution II; coating the pre-polymerization liquid II on the surface of a contact lens mold for heating and curing; and injecting the pre-polymerized liquid I into a mold for curing to obtain the contact lens with the surface hydrophilic coating. Phosphatidylcholine is adopted as a raw material to prepare the hydrophilic coating of the silicone hydrogel contact lens, the contact lens is of a three-layer structure, the outer layer is the hydrophilic gel coating and is soft and comfortable, the inner layer is a silicone hydrogel system and is high in oxygen permeability, the contact lens is more comfortable in the wearing process, and foreign body sensation can be effectively avoided.

The invention discloses a lipid nanoparticle loaded with SOX9siRNA (small interfering Ribonucleic Acid). The lipid nanoparticle is prepared from a tumor targeting carrier material and the SOX9siRNA. The tumor targeting carrier material is prepared from phospholipide-polyethylene glycol 2000 (DSPE-PEG2000-cRGDfk) modified by cRGDfK peptide, 4-(N, N-dimethylamino) butyric acid (dilinoleyl) methyl ester (DLin-MC3-DMA), distearoyl phosphatidylcholine (DSPC), dimyristoyl glycerol-polyethylene glycol 2000 (DMG-PEG2000) and cholesterol, and the preparation method of the tumor targeting carrier material is characterized in that the tumor targeting carrier material is prepared from the cRGDfK peptide modified phospholipide-polyethylene glycol 2000 (DSPE-PEG2000-cRGDfk), the 4-(N, N-dimethylamino) butyric acid (dilinoleyl) methyl ester (DLin-MC3-DMA) The prepared SOX9siRNA loaded lipid nanoparticles can be taken by colorectal cancer cells, lysosome escape is achieved, and proliferation, migration and invasion of the colorectal cancer cells are inhibited. Meanwhile, the compound also has good tumor targeting property, anti-tumor activity and safety in a colorectal cancer tumor-bearing mouse body.

The invention discloses application of a marker to preparation of a kit for diagnosing chronic obstructive pulmonary diseases. According to the application disclosed by the invention, the accuracy of diagnosing the chronic obstructive pulmonary disease by using (R)-3-hydroxytetradecanoic acid alone or in combination with the azelayl platelet activating factor is relatively high; on the basis of combination of (R)-3-hydroxytetradecanoic acid and an azelayl platelet activating factor, the compound is prepared. The compound can be further combined with one or two of 1-hexadecyl-2-(5-oxovaleryl)-sn-glycerol-3-phosphorylcholine, 1-O-hexadecyl-SN-glycerol-3-choline phosphoric acid, lauroyl-L-carnitine and beta-acetyl-gamma-O-alkyl-L-alpha-phosphatidylcholine to be used for diagnosing the chronic obstructive pulmonary disease. Therefore, a diagnostic kit for diagnosing the chronic obstructive pulmonary disease can be prepared on the basis of the scheme, and the kit contains a compound standard substance corresponding to the scheme and can also contain an internal standard compound for mass spectrum quantitative analysis.

The present invention relates to a composition for reducing local fat in an individual having local fat deposition without pain, edema or side effects using phosphatidylcholine, and a method of administration thereof, and more particularly to a composition for local fat reduction with reduced pain and side effects, comprising (i) phosphatidylcholine; and (ii) at least one selected from the group consisting of glycocholic acid (GCA), taurocholic acid (TCA) and their salts wherein the molar ratio (ii) / (i) of (i) and (ii) is 0.7-3.0, and wherein the composition is administered to the affected area of the individual at a concentration of 25-50 mg / mL at an interval of less than 4 weeks. The composition of the present invention provides a safe and stable formulation, is very effective in reducing adipocytes without various side effects, and can be administered to the affected area at shorter intervals to maximize the effect.

This invention discloses a food-grade nanoliposome and its preparation method. Phosphatidylcholine is dissolved in anhydrous ethanol to obtain an organic phase. Ultrapure water or the water-soluble substance 5(6)-carboxyfluorescein is used as the aqueous phase. The organic and aqueous phases are mixed using a microfluidic method or an ethanol injection method to form a uniform lipid film, resulting in nanoliposomes applicable to the food industry. The aqueous phase is encapsulated within the hydrophilic region of the liposome. Since the liposomes prepared by this invention do not contain cholesterol or other substances besides phosphatidylcholine and have a good encapsulation rate, replacing the aqueous phase with nutrients allows for long-term consumption as food without causing excessive cholesterol levels in the human body. Furthermore, the encapsulation of nutrients by liposomes can improve the absorption of nutrients by the human body, demonstrating significant application potential in the food industry.